Invention Grant
- Patent Title: Pyrimidine compounds that inhibit anaplastic lymphoma kinase
- Patent Title (中): 抑制间变性淋巴瘤激酶的嘧啶化合物
-
Application No.: US13697730Application Date: 2011-05-04
-
Publication No.: US08716281B2Publication Date: 2014-05-06
- Inventor: Marian C. Bryan , Alan C. Cheng , Elizabeth M. Doherty , James R. Falsey , Ingrid M. Fellows , Joseph L. Kim , Richard T. Lewis , Michele H. Potashman , Douglas A. Whittington
- Applicant: Marian C. Bryan , Alan C. Cheng , Elizabeth M. Doherty , James R. Falsey , Ingrid M. Fellows , Joseph L. Kim , Richard T. Lewis , Michele H. Potashman , Douglas A. Whittington
- Applicant Address: US CA Thousand Oaks
- Assignee: Amgen Inc.
- Current Assignee: Amgen Inc.
- Current Assignee Address: US CA Thousand Oaks
- Agency: Choate, Hall and Stewart LLP
- Agent Brenda Herschbach Jarrell; Kristen C. Buteau
- International Application: PCT/US2011/035186 WO 20110504
- International Announcement: WO2011/143033 WO 20111117
- Main IPC: A61K31/18
- IPC: A61K31/18
Abstract:
The present invention describes pyrimidine compounds of Formula I that are useful as anaplastic lymphoma kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
Public/Granted literature
- US20130158019A1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE Public/Granted day:2013-06-20
Information query
